I'm with you there ABDM & i've said ad nauseum how the board continuing to restate guidance after it's been missed time & time again has a signifcant impact on the stock, confidence & their own credibility however i'll just throw in my 2 cents on a few points in your post.
> Dougies getting on (don't take it to heart if you're reading it) but all of the companys & there are a few where he is on the board his holdings are minimal if at all - i take it as he's more than happy to work on soley the renumeration, look at his past & it really seems it's probably always been that way - academic, high profile jobs with big pharma list goes on - just old school i'd say it's about the job & the company not the stock market or self investment.
> Le Métier ? - i pretty much shrugged at that anyway, i'm not really a fan of drug discovery companies branching into cosmetics but eh maybe it will suprise one day, the phylomer was sitting idle so why not pass it off with a non exclusive license in the mean time - somethings better than nothing.
> Just on words like "CHUNKY" & "SIGNIFICANT" yeh i'm with you there words are words numbers speak louder - i've learnt ot not pay to much attention to anything else
On your 3 overdue deals not trying to dampen further but it's actually 5 overdue although most likely they went AWOL >> 0/3 in 2011 >> 1/3 2012 ...... Still really not sure how to explain what happened when they where overly confident in meeting guidance each year right to the end yet non matured, of course they highlight big pharma restructuring & delays put upon the negotiations but i think there is more to it you don't turn to those hit/miss scenarios on that alone.
I think DW on Janssen is on the money they've stepped up milestones progressively on each of the deals to date Roche <$100M, AZ $100M, Pfizer $134M so fair to assume Janssen is up a notch on Pfizer multiply that against each target & it brings it about consumerate with other deals.
If we're to assume (a dangerous thing around here lol) that everything is progressing in current partnerships then the first 6 months of the year should shape what lies ahead with licenseing & decisions from most coming in the near term. Roche, Pfizer & maayyybe AZ ? That's the big ticket imo not only funds secured but it will up the pace of new partners putting ink to paper - validation of the library & platform comes with those licenses.
I'm still convinced they've got big moves ahead, it might just take a while - i never fall in love with stocks but i'll go down the river with this donkey :-) lol
PYC Price at posting:
2.4¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)